Evidence map›Paper›PMID 37537907›Full record

ArticleJournal of telemedicine and telecare2025

Telemedicine-delivered treatment for substance use disorder: A scoping review.

Huyen Pham, Chunqing Lin, Yuhui Zhu, Sarah E Clingan, Lewei Allison Lin, Larissa J Mooney, Sean M Murphy, Cynthia I Campbell, Yanping Liu, Yih-Ing Hser

Open access · greenAbstract readScoping Review
In one paragraph

Article in Journal of telemedicine and telecare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Regulation and Compliance in Telemedicine: Viewpoint.Journal of medical Internet research · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Huyen PhamDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, USA.ORCID 0000-0002-2429-5224
Chunqing LinDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, USA.
Yuhui ZhuDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, USA.
Sarah E ClinganDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, USA.
Lewei Allison LinDepartment of Psychiatry, University of Michigan, Ann Arbor, USA.
Larissa J MooneyDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, USA.
Sean M MurphyDepartment of Population Health Sciences, Weill Cornell Medical College, New York, USA.ORCID 0000-0001-9104-0670
Cynthia I CampbellCenter for Addiction and Mental Health Research, Division of Research, Kaiser Permanente Northern California, Oakland, USA.
Yanping LiuCenter for Clinical Trials Network, National Institute on Drug Abuse, Bethesda, USA.
Yih-Ing HserDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, USA.
University of California, Los Angeles · USCornell University · USKaiser Permanente · USNational Institute on Drug Abuse · USUniversity of Michigan · US

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
Greater Southern California Node of the Clinical Trials NetworkUG1DA049435 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YIH-ING HSER · 2019 to 2026
$16.7M
HSRD VA IK2 HX002612NIDA NIH HHS UG1 DA040314NIDA NIH HHS UG1 DA049435NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

IntroductionThe COVID pandemic prompted a significant increase in the utilization of telemedicine (TM) for substance use disorder (SUD) treatment. As we transition towards a "new normal" policy, it is crucial to comprehensively understand the evidence of TM in SUD treatment. This scoping review aims to summarize existing evidence regarding TM's acceptability, quality, effectiveness, access/utilization, and cost in the context of SUD treatment in order to identify knowledge gaps and inform policy decisions regarding TM for SUDs.MethodWe searched studies published in 2012-2022 from PubMed, Cochrane Library, Embase, Web of Science, and other sources. Findings were synthesized using thematic analysis.ResultsA total of 856 relevant articles were screened, with a final total of 42 articles included in the review. TM in SUD treatment was perceived to be generally beneficial and acceptable. TM was as effective as in-person SUD care in terms of substance use reduction and treatment retention; however, most studies lacked rigorous designs and follow-up durations were brief (≤3 months). Telephone-based TM platforms (vs video) were positively associated with older age, lower education, and no prior overdose. Providers generally consider TM to be affordable for patients, but no relevant studies were available from patient perspectives.ConclusionsTM in SUD treatment is generally perceived to be beneficial and acceptable and as effective as in-person care, although more rigorously designed studies on effectiveness are still lacking. Access and utilization of TM may vary by platform. TM service quality and costs are the least studied and warrant further investigations.

Indexed as

Substance-Related DisordersTelemedicineCOVID-19Health Services AccessibilityHumansacceptabilityaccesseffectivenessqualitysubstance use disorderTelemedicine

Identifiers

PMID37537907
PMCPMC11444076
OpenAlexW4385564469

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.